CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: TOX is a diagnostic marker for cutaneous T-cell lymphomas (CTCL) and is overexpressed in affected CD4+ cells [37] Retinoids have been successfully used in the therapy of CTLC for over 30 years [38] and are still being used in T-cell lymphoma therapy [39].